Li H, Chen M, Liang S, et al. - Researchers examined whether and how different doses of vitamin B6 intake were related to nasopharyngeal carcinoma (NPC) prognosis, in this retrospective cohort study. Participants were 792 newly diagnosed NPC patients, who received a median follow-up of 62.05 months. Patients with NPC were split into three groups based on the cut-off value of vitamin B6 during treatment (VB6DT): non-users (0 mg/d), VB6DT > 8.6 mg/d, and VB6DT ≤ 8.6 mg/d. Significantly lower 5-year overall survival (OS), distant metastasis-free survival, and progression-free survival as well as slightly but not significantly lower 5-year local recurrence-free survival were observed in patients with VB6DT > 8.6 mg/d vs the non-users. In NPC patients, excessive VB6DT higher than the cut-off value was concluded as an independent negative prognostic factor. In addition, OS was improved only slightly but not significantly in correlation with low dose intake.